Nội dung chính của bài viết
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that is most commonly seen in premature infants who require prolonged mechanical ventilation and oxygen therapy. 75% of intubated infants have episodes of dysfunctional surfactants associated with lower levels of surfactant proteins. This study aims to evaluate the effectiveness of late surfactant therapy in treating BPD in premature infants. Nineteen preterm infants diagnosed with severe BPD requiring mechanic ventilation, according to Jobe and Bancalari, were treated with surfactant (Poractant alpha 100mg/kg intra-tracheal). Patients were observed for change in oxygen requirement before and at 1-h, 6-h, 12-h, 24-h, and 48-h after treatment. There were 13 boys and 6 girls; boy to girl ratio was 2.16/1. The mean gestation age was 28.3 ± 2 weeks; the mean birth weight was 1134.7 ± 314 gram. There was an increase in SpO2 (saturation of peripheral oxygen), PaO2 (the partial pressure of oxygen in arterial blood) and reduction in FiO2 (fraction of inspired oxygen), PaCO2 (the partial pressure of carbon dioxide in arterial blood), OI (oxygen index), MAP (mean airway pressure) and AaDO2 (Alveolar-to-arterial oxygen gradient) after surfactant (p < 0.05). Conclusion: In patients with severe BPD, late surfactant therapy has shown initial benefits in lung functions and reducing oxygen requirement.
Chi tiết bài viết
bronchopulmonary dysplasia, premature infants, late surfactant therapy
Tài liệu tham khảo
2. Jeon, G. W. Changes in the Incidence of Bronchopulmonary Dysplasia among Preterm Infants in a Single Center over 10 Years. Neonatal medicine. 2020;27(1):1-7.
3. Carly M. Gisondo, S. M. D. Bronchopulmonary Dysplasia: An Overview. Research and Reports in Neonatology. 2020;10:67-79.
4. Michael, Z., Spyropoulos, F., Ghanta, S. & Christou, H. Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches. Clin Med Insights Pediatr. 2018;12.
5. Merrill, J. D, et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res. 2004;56:918-926.
6. Keller, R. L, et al. Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study. Pediatr Res. 2012;72:613-619.
7. Laughon, M., et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics. 2009;123:89-96.
8. Hascoët, J. M., et al. Late Surfactant Administration in Very Preterm Neonates With Prolonged Respiratory Distress and Pulmonary Outcome at 1 Year of Age: A Randomized Clinical Trial. JAMA Pediatr. 2016;170:365-372.
9. Jobe, A. H., Bancalari, E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-1729.
10. Pandit, P. B., Dunn, M. S., Kelly, E. N., Perlman, M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics. 1995;95:851-854.
11. Digeronimo, R. J., et al. Mechanical ventilation down-regulates surfactant protein A and keratinocyte growth factor expression in premature rabbits. Pediatr Res. 2007;62:277-282.